DNA-mediated immunization of glycoprotein 350 of Epstein-Barr virus induces the effective humoral and cellular immune responses against the antigen

Molecules and Cells

Volumn 12, Issue 1, 2001, Pages 41-49

  Jung, Sojin ^a   Chung, Young Kwan ^a   Chang, Sun Hwa ^a   Kim, Ju ^a   Kim, Hak Ryul ^a   Jang, Hyon Seok ^b   Lee, Jeong Chae ^a   Chung, Gook Hyun ^a   Jang, Yong Suk ^a  

^a Chonbuk National University   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Antibody; Cytotoxic T Lymphocyte; DNA Vaccine; Epstein Barr Virus; gp350

Indexed keywords

DNA VACCINE; GP 300 350, EPSTEIN BARR VIRUS; GP 300-350, EPSTEIN-BARR VIRUS; MATRIX PROTEIN; MEMBRANE PROTEIN; RECOMBINANT PROTEIN; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL CULTURE; CYTOTOXICITY; CYTOTOXICITY TEST; EPSTEIN BARR VIRUS; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE; PLASMID; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; GENETIC VECTORS; HERPESVIRUS 4, HUMAN; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; PLASMIDS; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; VACCINES, DNA; VIRAL MATRIX PROTEINS; VIRAL VACCINES;

EID: 0035980158     PISSN: 10168478     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Ambinder, R. F., Robertson, K. D., Moore, S. M., and Yang, J. (1996) Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma. Semin. Cancer Biol. 7, 217-226.
2. Anzano, M. A., Roberts, A. B., Smith, J. M., Sporn, M. B., and De Larco, J. E. (1983) Sarcoma growth factor from conditioned medium of virally transformed cells is composed of both type alpha and type beta transforming growth factors. Proc. Natl. Acad. Sci. USA 80, 6264-6268.
3. Arulkanthan, A., Brown, W. C., McGuire, T. C., and Knowles, D. P. (1999) Biased immunoglobulin G1 isotype responses induced in cattle with DNA expressing msp1a of Anaplasma marginale. Infect. Immun. 67, 3481-3487.
4. Brattain, M. G., Strobel-Stevens, J., Find, D., Webb, M., and Sarrif, A. M. (1980) Establishment of mouse colonie carcinoma cell lines with different metastatic properties. Cancer Res. 40, 2142-2146.
5. Chang, S.-H., Kim, S.-H., Lee, W.-K., Kim, H.-J., Choi, S.-H., Park, J.-H., Jang, H.-S., Chung, G.-H., Kwon, T.-H., Kim, D.-H., Yang, M.-S., and Jang, Y.-S. (1998) Cloning and analysis of the Epstein-Barr virus glycoprotcin 350 genes. Mol. Cells 8, 585-593.
6. Charo, J., Ciupitu, A. M., De Preville, A. L. C., Triverdi, P., Klein, G., Himkula, J., and Kiessling, R. (1999) A long-term memory obtained by genetic immunization results in full protection from a mammary adenocarcinoma expressing an EBV gene. J. Immunol. 163, 5913-5919.
7. Chen, S. C., Jones, D. H., Fynan, E. F., Farrar, G. H., Clegg, J. C., Greenberg, H. B., and Herrmann, J. E. (1998) Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J. Virol. 72, 5757-5761.
8. Davis, H. L., Michel, M. L., and Whalen, R. G. (1993) DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum. Mol. Genet. 2, 1847-1851.
9. De Schryver, A., Klein, G., Hewetson, J., Rocchi, G., Henle, W., Henle, G., Moss, D. J., and Pope, J. H. (1974) Comparison of EBV neutralization tests based on abortive infection or transformation of lymphoid cells and their relation to membrane reactive antibodies (anti MA). Int. J. Cancer 13, 353-362.
10. Emini, E. C., Schleif, W. A., Armstrong, M. E., Silberklang, M., Schultz, L. D., Lehman, D., Maigetter, R. Z., Qualtiere, L. F., Pearson, G. R., and Ellis, R. W. (1988) Antigenic analysis of the Epstein-Barr virus major membrane antigen (gp350/220) expressed in yeast and mammalian cells: implications for the development of a subunit vaccine. Virology 166, 387-393.
11. Gu, S.-Y., Huang, T.-M., Ruan, L., Miao, Y.-H., Lu, H., Chu, C-M., Motz, M., and Wolf, H. (1995) First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev. Biol. Stand. 84, 171-177.
12. Haan, K. M., Kwok, W. W., Longnecker, R., and Speck, P. (2000) Eipstein-Barr virus entry utilizing HLA-DP or HLA-DQ as a coreceptor. J. Virol. 74, 2451-2454.
13. Henle, G., Henle, W., and Diehl, V. (1968) Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis. Proc. Natl. Acad. Sci. USA 59, 94-101.
14. Hessing, M., van Schijndel, H. B., van Grunsven, W. M., Wolf, H., and Middeldorp, J. M. (1992) Purification and quantification of recombinant Epstein-Barr viral glycoprotein gp350/ 220 from Chinese hamster ovary cells. J. Chromatog. 599, 267-272.
15. Jackman, W. T., Mann, K. A., Hoffmann, H. J., and Spaete, R. R. (1999) Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine. Vaccine 17, 660-668.
16. Jilg, W., Bogedain, C., Mairhofer, H., Gu, S. Y., and Wolf, H. (1994) The Epstein-Barr virus-encoded glycoprotein gp110 (BALF 4) can serve as a target for antibody-dependent cell-mediated cytotoxicity (ADCC). Virology 202, 974-977.
17. Jones, D. H., Clegg, J. C., and Farrar, G. H. (1998) Oral delivery of micro-encapsulated DNA vaccines. Dev. Biol. Stand. 92, 149-155.
18. Kaneko, H., Bednarek, I., Wierzbicki, A., Kiszka, I., Dmochowski, M., Wasik, T. J., Kaneko, Y., and Kozbor, D. (2000) Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein. Virology 267, 8-16.
19. Kawabata, S., Terao, Y., Fujiwara, T., Nakagawa, I., and Hamada, S. (1999) Targeted salivary gland immunization with plasmid DNA elicits specific salivary immunoglobulin A and G antibodies and serum immunoglobulin G antibodies in mice. Infect. Immun. 67, 5863-5868.
20. Khanna, R., Sherritt, M., and Burrows, S. R. (1999) EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design. J. Immunol. 162, 3063-3069.
21. Khyatti, M., Patel, P. C., Stefanescu, I., and Menezes, J. (1991) Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity. J. Virol. 65, 996-1001.
22. Kochel, T. J., Raviprakash, K., Hayes, C. G., Watts, D. M., Russell, K. L., Gozalo, A. S., Phillips, I. A., Ewing, D. F., Murphy, G. S., and Porter, K. R. (2000) A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys. Vaccine 18, 3166-3173.
23. Konishi, E., Yamaoka, M., Kurane, I., and Mason, P. W. (2000) A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice. Vaccine 18, 1133-1139.
24. Lee, W. K., Kim, S. M., Sim, Y. S., Cho, S. G., Park, S. H., Kim, C. W., and Park, J.-G. (1998) B-lymphoblastoid cell lines from cancer patients. In Vitro Cell Dev. Biol. Anim. 34, 97-100.
25. Lees, J. F., Arrand, J. E., Pepper, S. D., Stewart, J. P., Mackett, M., and Arrand, J. R. (1993) The Epstein-Barr virus candidate vaccine antigen gp340/220 is highly conserved between virus types A and B. Virology 195, 578-586.
26. Madej, M., Conway, M. J., Morgan, A. J., Sweet, J., Wallace, L., Qualtiere, L. F., Arrand, J. R., and Mackett, M. (1992) Purification and characterization of Epstein-Barr virus gp350/220 produced by a bovine papillomavirus virus expression vector system. Vaccine 10, 777-782.
27. Magrath, I., Jain, V., and Bhatia, K. (1992) Epstein-Barr virus and Burkitt's lymphoma. Semin. Cancer Biol. 3, 285-295.
28. McCluskie, M. J., Brazolot Millan, C. L., Gramzinski, R. A., Robinson, H. L., Santiro, J. C., Fuller, J. T., Widera, G., Haynes, J. R., Purcell, R. H., and Davis, H. L. (1999) Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol. Med. 5, 287-300.
29. Miller, G., Shope, T., Lisco, H., Stitt, D., and Lipman, M. (1972) Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. Proc. Natl. Acad. Sci. USA 69, 383-387.
30. Molesworth, S. J., Lake, C. M., Borza, C. M., Turk, S. M., and Hutt-Fletcher, L. M. (2000) Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells. J. Virol. 74, 6324-6332.
31. Mor, G., Klinman, D. M., Shapiro, S., Hagiwara, E., Sedegah, M., Norman, J. A., Hoffman, S. L., and Steinberg, A. D. (1995) Complexity of the cytokine and antibody response elicited by immunizing mice with Plasmodium yoelii circumsporozoite protein plasmid DNA. J. Immunol. 155, 2039-2046.
32. Morgan, A. J., Allison, A. C., Finerty, S., Scullion, F. T., Byars, N. E., and Epstein, M. A. (1989) Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use. J. Med. Virol. 29, 74-78.
33. Moss, D. J., Schmidt, C., Elliott, S., Suhrbier, A., Burrows, S., and Khanna, R. (1996) Strategies involved in developing an effective vaccine for EBV-associated diseases. Adv. Cancer Res. 69, 213-245.
34. Nemerow, G. R., Mold, C., Schwend, V. K., Tollefson, V., and Cooper, N. R. (1987) Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J. Virol. 61, 1416-1420.
35. Niedobitek, G., Agathanggelou, A., and Nicholls, J. M. (1996) Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: viral gene expression, turior cell phenotype, and the role of the lymphoid stroma. Semin. Cancer Biol. 7, 165-174.
36. Pardoll, D. M. and Beckerleg, A. M. (1995) Exposing the immunology of naked DNA vaccines. Immunity 3, 65-169.
37. Park, J.-H., Kim, C.-J., Lee, J.-H., Shin, S.-H., Chung, G.-H., and Jang, Y.-S. (1999) Effective immunotherapy of cancer by DNA vaccination. Mol. Cells 9, 384-391.
38. Patel, P. C. and Menezes, J. (1982) Epstein-Barr virus (EBV)-lymphoid cell interactions. II. The influence of the EBV replication cycle on natural killing and antibody-dependent cellular cytotoxicity against EBV-infected cells. Clin. Exp. Immunol. 48, 589-601.
39. Pearson, G., Dewey, F., Klein, G., Henle, G., and Henle, W. (1970) Relation between neutralization of Epste n-Barr virus and antibodies to cell-membrane antigens induced by the virus. J. Natl. Cancer Inst. 45, 989-995.
40. Pither, R. J., Zhang, C. X., Shiels, C., Tarlton, J., Finerty, S., and Morgan, A. J. (1992a) Mapping of B-cell epilopes on the polypeptide chain of the Epstein-Barr virus major envelope glycoprotein and candidate vaccine molecule gp340. J. Virol. 66, 1246-1251.
41. Pither, R. J., Nolan, L., Tarlton, J., Walford, J., and Morgan, A. J. (1992b) Distribution of epitopes within the amino acid sequence of the Epstein-Barr virus major envelope glycoprotein, gp340, recognized by hyperimmune rabbit sera. J. Gen. Virol. 73, 1409-1415.
42. Ragot, T., Finerty, S., Watkins, P. E., Perricaudet, M., and Morgan, A. J. (1993) Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induccd lymphomas in the cottontop tamarin. J. Gen. Virol. 74, 501-507.
43. Ranieri, E., Herr, W., Gambotto, A., Olson, W., Rowe, D., Robbins, P. D., Kierstead, L. S., Watkins, S. C., Gesualdo, L., and Storkus, W. J. (1999) Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination. J. Virol. 73, 10416-10425.
44. Rickinson, A. B. (1995) Immune intervention against virus-associated human cancers. Ann. Oncol. 6, S69-S71.
45. Tanner, J., Weis, J., Fearon, D., Whang, Y., and Kieff, E. (1987) Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell 50, 203-213.
46. Tanner, J. E., Wei, M. X., Alfieri, C., Ahmad, A., Taylor, P., Ooka, T., and Menezes, J. (1997) Antibody and antibody-dependent cellular cytotoxicity response against the BamHI A rightward open-reading frame-1 protein of Epstein-Barr virus (EBV) in EBV-associated disorders. J. Infect. Dis. 175, 38-46.
47. Thomas, J. A. and Crawford, D. H. (1989) Epstein-Barr virus associated B-cell lymphomas in AIDS and after organ transplantation. Lancet 1, 1075-1076.
48. Thomas, J. A., Allday, M. J., and Crawford, D. H. (1991) Epstein-Barr virus-associated lymphorpoliferative disorders in immunocompromised individuals. Adv. Cancer Res. 51, 329-380.
49. van Drunen Littel-van den Hurk, Braun, R. P., Lewis, P. J., Karvonen, B. C., Baca-Estrada, M. E., Snider, M., McCartney, D., Watts, T., and Babiuk, L. A. (1998) Intradermal immunization with a bovine herpesvirus-1 DNA vaccine induces protective immunity in cattle. J. Gen. Virol. 79, 831-839.
50. Waisman, A., Ruiz, P. J., Hirschberg, D. L., Gelman, A., Oksenberg, J. R., Brocke, S., Mor, F., Cohen, I. R., and Steinman, L. (1996) Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nat. Med. 2, 899-905.
51. Weber, J. S. and Rosenberg, S. A. (1988) Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res. 48, 5818-5824.
52. Wells, A., Koide, N., and Klein, G. (1982) Two large virion envelope glycoproteins mediate Epstein-Barr virus binding to receptor-positive cells. J. Virol. 41, 286-297.
53. Wilson, A. D. and Morgan, A. J. (1998) Indirect measurement of Epstein-Barr virus neutralizing antibodies by ELISA. J. Virol. Methods 73, 11-19.
54. Wu, T. C., Mann, R. B., Charache, P., Hayward, S. D., Staal, S., Lambe, B. C., and Ambinder, R. F. (1990) Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int. J. Cancer 46, 801-804.
55. Yankauckas, M. A., Morrow, J. E., Parker, S. E., Abai, A., Rhodes, G. H., Dwarki, V. J., and Gromkowski, S. H. (1993) Long-term anti-nucleoprotein cellular and humoral immunity is induced by intramuscular injection of plasmid DNA containing NP gene. DNA Cell Biol. 12, 771-776.